What is dihydrohonokiol B?
dihydrohonokiol b is a derivative of honokiol, a bioactive compound found in the bark and leaves of magnolia trees. The chemical structure of the two substances is different because of the saturation of the double bonds, and Dihydrohonokiol is the dihydrogenated form of honokiol, as well as its reductive form. Due to the addition of hydrogen atoms in its structure, double bond saturation exists in the Dihydrohonokiol structure.
1. Product Introduction
Dihydrohonokiol B (DHH-B) is a high-activity bioactive derivative of Honokiol, naturally extracted and reduced from magnolia tree bark and leaves. Structurally, Dihydrohonokiol B is the dihydrogenated and reduced form of Honokiol. With hydrogen atom addition and double bond saturation in its molecular structure, it possesses different chemical characteristics and better biological potency compared with conventional Honokiol.
DHH-B exhibits more powerful GABA receptor modulation capacity than Honokiol while maintaining higher safety, making it a superior natural active ingredient for anxiety relief, sleep support and neuroprotection. Our Dihydrohonokiol B powder reaches a high purity of 99.15% (HPLC), with full physical, heavy metal and microbiological indicators fully compliant with enterprise quality standards.

| Testing Items | Specification | Results | Method |
| Appearance | White powder | Conform | Organoleptic |
| Identification | Data of HNMR is conform to chemical structure | Conform | HNMR |
| Melting point | 95-99℃ | 97-98℃ | |
| Purity (HPLC) | ≥98% | 99.15% | HPLC |
| Water Content | ≤1% | 0.12% | Karl Fischer Titration |
| Lead (Pb) | ≤5.0ppm | Not Detected | GB5009.12-2017 |
| Arsenic (As) | ≤2.0ppm | Not Detected | GB5009.11-2014 |
| Mercury (Hg) | ≤0.3ppm | Not Detected | GB5009.17-2021 |
| Total Plate Count | ≤1,000cfu/g | ≤30cfu/g | GB4789.2-2016 |
| Yeast & Mold | ≤100cfu/g | ≤30cfu/g | GB4789.15-2016 |
| Salmonella | Negative | Not Detected | GB4789.4-2016 |
| E.Coli | Negative | Not Detected | GB4789.3-2016 |
| Staphylococcus Aureus | Negative | Not Detected | GB4789.10-2016 |
| Conclusion | The product complies with the enterprise standard | ||
What are the effects of DHH B?
1. Dihydrohonokiol has been examined for its significant anxiolytic (anti-anxiety) and sedative properties, which are similar to honokiol. According to research, dihydrohonokiol may be more effective than honokiol at modulating GABA receptors, which are important for reducing anxiety and promoting relaxation.
2. Neuroprotection: Like honokiol, dihydrohonokiol has neuroprotective effects. It can assist neurons resist damage induced by excitotoxicity and oxidative stress.
3. Dihydrohonokiol enhances GABAergic activity, increasing the inhibitory neurotransmitter in the brain. This calms the central nervous system, reducing anxiety and promoting sleep.
4. Potential Therapeutic Uses:
(1). Anxiety Disorders: Dihydrohonokiol is being studied for its potential to treat anxiety disorders due to its high GABA modulation and lack of some of the negative effects associated with current anxiolytic medications.
(2). Insomnia: Because of its sedative characteristics, dihydrohonokiol may be studied as a therapy for sleep disorders.
(3). Neuroprotection: Because of its antioxidant and neuroprotective properties, it may be useful in protecting the brain against neurodegenerative diseases.

1. Used in pharmaceutical synthesis.
2. Used in pharmacological research.
3. Used in supplements.
Reference
[1]. Does dihydrohonokiol, a potent anxiolytic compound, result in the development of benzodiazepine-like side effects?
Kuribara H, Kishi E, Maruyama Y.J Pharm Pharmacol. 2000 Aug;52(8):1017-22. doi: 10.1211/0022357001774741.
2.Core Functions & Mechanisms
Dihydrohonokiol B is a superior natural anxiolytic and neuroprotective active ingredient with stronger GABA regulatory activity than ordinary Honokiol, featuring mild action and no obvious side effects of traditional sedative drugs:
- Powerful Anti-anxiety & Sedative Effect: DHH-B significantly enhances GABAergic inhibitory activity in the brain, increases the level of inhibitory neurotransmitters, calms the overexcited central nervous system, and effectively relieves anxiety, tension and irritability.
- Improve Sleep Quality: With excellent sedative properties, it helps shorten sleep onset time, stabilize sleep cycle and improve insomnia symptoms without causing drowsiness dependence.
- Excellent Neuroprotection: Resists neuronal damage caused by oxidative stress and excitotoxicity, protects nerve cell activity, and effectively prevents and relieves neurodegenerative damage.
- Safer GABA Regulation: Compared with traditional benzodiazepine sedatives, DHH-B regulates GABA receptors efficiently without inducing drug dependence or similar side effects, with higher safety.
3.Potential Therapeutic Value
- Anxiety Disorder Improvement: As a natural alternative to synthetic anxiolytic drugs, DHH-B has great research and application potential for adjuvant treatment of anxiety disorders.
- Insomnia & Sleep Disorder Treatment: Reliable sedative and calming effects make it an ideal raw material for natural sleep-improving products.
- Neurodegenerative Protection: Its antioxidant and neuroprotective properties help protect brain nerves and assist in the prevention of neurodegenerative diseases.
4.Wide Application Fields
- Health Supplement Industry: Applied in natural anti-anxiety, stress relief and sleep support dietary supplements.
- Pharmaceutical Research & Synthesis: Used as a core raw material for new sedative and anxiolytic drug synthesis and pharmaceutical intermediate research.
- Pharmacological Experimental Research: Widely used in GABA receptor mechanism, neuroprotection and psychopharmacology related scientific research.






Hot Tags: Dihydrohonokiol B, China Dihydrohonokiol B manufacturers, suppliers, factory, Superoxide Dismutase Powder, Magnesium malate trihydrate, GABA Powder, Gamma Amino Butyric Acid, Magnesium Bisglycinate CAS 14783-68-7, GABA CAS 56 12 2
